NanoViricides, Inc. (NYSE American: NNVC) announced that its clinical-stage antiviral drug NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity, which can significantly aid the company's regulatory advancement of the drug candidate.
The designation underscores the importance of developing effective treatments for measles, a disease experiencing a resurgence globally due to declining vaccination rates. NV-387 is a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles, positioning it as a potential therapeutic option to address these outbreaks.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed as a treatment for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections. Additionally, NV-387 has shown efficacy in animal models for monkeypox (MPox), smallpox, and measles.
The company's other advanced drug candidate is NV-HHV-1, intended for the treatment of all herpesvirus infections, including HSV-1 (cold sores), HSV-2 (genital ulcers), VZV (shingles and chickenpox). However, NanoViricides cannot project an exact date for filing an Investigational New Drug (IND) application for any of its drugs due to dependence on external collaborators and consultants.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The company is currently focused on advancing NV-387 into Phase II human clinical trials, a critical step toward potential commercialization.
The Orphan Drug Designation is a significant milestone for NanoViricides, as it provides incentives that can reduce development costs and accelerate the path to market. The designation also highlights the FDA's recognition of the unmet medical need for measles treatments, especially in light of recent global outbreaks.
For more information about NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC. The full press release regarding the Orphan Drug Designation can be accessed at https://ibn.fm/uIWWv.
